Title

Presence of cells in the polyaneuploid cancer cell (PACC) state predicts risk of recurrence in prostate

Authors

Levent Trabzonlu, Kenneth J. Pienta, Bruce J. Trock, Angelo M. De Marzo, Sarah R. Amend

KJP, SRA: Cancer Ecology Center, The Brady Urological Institute, Johns Hopkins University School of Medicine

BJT: The Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, MD 21287 LT: Department of Pathology and Laboratory Medicine, Loyola University Medical Center, Maywood, IL 60153

AMD: Departments of Pathology, Urology and Oncology, The Johns Hopkins University School of Medicine. The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Abstract

Background: The non-proliferating polyaneuploid cancer cell (PACC) state is associated with therapeutic resistance in cancer. A subset of cancer cells enters the PACC state by polyploidization and acts as cancer stem cells by undergoing depolyploidization and repopulating the tumor cell population after the therapeutic stress is relieved. Our aim was to systematically assess the presence and importance of this entity in men who underwent radical prostatectomy with curative intent to treat their presumed localized PCa.

Materials and Methods: Men with NCCN intermediate- or high-risk PCa who underwent radical prostatectomy I from 2007-2015 and who did not receive neoadjuvant treatment were included. From the cohort of 2159 patients, the analysis focused on a subcohort of 209 patients was selected, and 38 cases. Prostate tissue microarrays (TMAs) were prepared from formalin-fixed paraffin-embedded blocks of the radical prostatectomy specimens. A total of 2807 tissue samples of matched normal/benign and cancer were arrayed in 9 TMA blocks. The presence of PACCs and the number of PACCs on each core were noted.

Results: The total number of PACCs and the total number of cores with PACCs were significantly correlated with increasing Gleason score (p=0.0004) and increasing CAPRA-S (p=0.004), but no other variables. In univariate proportional hazards models of metastasis-free survival, year of surgery, Gleason score (9-10 vs. 7-8), pathology stage, CAPRA-S, total PACCs, and cores positive for PACCs were all statistically significant. The multivariable models with PACCs that gave the best fit included CAPRA-S. Adding either total PACCs or cores positive for PACCs to CAPRA-S both significantly improved model fit compared to CAPRA-S alone.

Conclusion: Our findings show that the number of PACCs and the number of cores positive for PACCs are statistically significant prognostic factors for metastasis-free survival, after adjusting for CAPRA-S, in a case-cohort of intermediate- or high-risk men who underwent radical prostatectomy. In addition, despite the small number of men with complete data to evaluate time to mCRPC, the total number of PACCs was a statistically significant predictor of mCRPC in univariate analysis, and suggested a prognostic effect even after adjusting for CAPRA-S.

Introduction

Therapeutic resistance in cancer is generally attributed to the existence of resistant cell clones ¹⁻³. The resistant clones are thought to be generated through either intrinsic genetic instability resulting in tumor cell heterogeneity (TCH) or a cancer stem cell (CSC) population ^{4–7}. The resistant clones allow for regrowth of the cancer cell population after treatment insult. There is a growing body of evidence that the phenomenon of therapeutic resistance may be explained by a poorly recognized but distinct cell state. This cell state is documented as the non-proliferating polyaneuploid cancer cell (PACC) state, induced by tumor microenvironmental (intrinsic) or therapeutic (extrinsic) stress 8-10. A doubling of a cancer cell's aneuploid genome combined with an exit from the cell cycle enables the PACC state. The cell state can exist for an extended period of time. In response to stress, a subset of cancer cells enter the PACC state by accessing an evolutionary or developmental polyploidization program. Once that stress is relieved, cells in the PACC state can act as CSCs by undergoing depolyploidization and repopulating the tumor cell population. The role of the PACC state for therapeutic resistance adds to those of CSC and TCH. Identifying cells in the PACC state in patients may have important diagnostic, prognostic, and therapeutic implications.

Large pleomorphic cancer cells with irregular nuclei have been documented in histopathologic specimens of multiple tumor types since the 1800s 11. These cells have been reported utilizing a variety of names: polyaneuploid cancer cells (PACCs), polyploid giant cancer cells (PGCCs), giant cancer cells (GCCs), multinucleated giant cancer cells (MNGCCs), blastomere-like cancer cells, osteoclast-like cancer cells, cells in an embryonic diapause, pleomorphic giant cells, large stem cells, and persister cells ^{12–23}. Recent data indicates that these cells do not represent a different type of cancer cell within the heterogeneous tumor cell population but rather a specific non-proliferative, polyaneuploid cell state 8-10. In response to therapeutic stress, this cell state enables survival and is responsible for driving therapeutic resistance to nearly all available treatment regimens.

The presence of cells in the PACC state has been documented in virtually all cancer types including adenocarcinomas, transitional cell tumors, squamous cell carcinomas, leukemias, lymphomas, glioblastomas, and sarcomas ^{12,24–29}. Most often observed in metastatic cancers or after treatment, their importance for patient prognosis has been understudied 30,31. In glioma, Qu and colleagues analyzed 76 patients and reported that the number of PACCs increased with the grade of tumors ³². In a study of 47 patients with anorectal melanoma, the number of PACCs was demonstrated to increase with tumor size ³³. In laryngeal cancer, Liu and colleagues analyzed the presence of PGCCs in 102 patients and found that patients with high expression of PGCCs had a poorer prognosis ³⁴. In breast cancer, Fei and colleagues analyzed 167 histopathologic specimens including benign tissue, primary breast tumors, and lymph node metastases and found the highest number of PGCCs in the lymph node metastases of the breast cancer patients 30. In a study of 30 patients, Gerashchenko and colleagues reported that breast tumors with higher proportion of polyploid cells was a marker of poor response to neoadjuvant chemotherapy ³⁵. Lv and colleagues investigated the presence of PGCCs with budding in 80 patients with serous ovarian tumors and found that the presence of PGCCs in the primary tumor correlated with metastasis ³⁶. Zhang and colleagues examined tissue from 159 patients with colorectal cancer and demonstrated that the presence of PGCCs with budding increased as tumors became more de-differentiated ³⁷.

The presence of cancer cells in the PACC state has been reported in prostate cancer (PCa) 12,38. In an autopsy study of PCa patients who had failed multiple lines of therapy, Mannan and colleagues reported the presence of multiple cells with highly irregular polylobulated nuclei or multiple pleomorphic nuclei 39. Alharbi and colleagues reported a series of 30 patients with a rare variant of PCa with focal pleomorphic giant cell features that were extremely aggressive and associated with poor outcomes ⁴⁰. This study was undertaken to systematically assess the presence and importance of cells in the PACC state in men who underwent radical prostatectomy with curative intent to treat their presumed localized PCa.

Materials and Methods Patients

Men with NCCN intermediate- or high-risk PCa who underwent radical prostatectomy at Johns Hopkins Hospital from 2007-2015 and who did not receive neoadjuvant treatment were identified from the Institutional Review Board-approved Brady Urological Institute Radical Prostatectomy database. Intermediate risk was defined as clinical stage T2b-T2c, or biopsy Gleason grade groups 2-3, or PSA 10-20 ng/ml, and high risk was defined as biopsy Gleason grade groups 4-5 or clinical stage T3, or

PSA>20 ng/ml (2). There were 3685 men with NCCN intermediate- or high-risk PCa with radical prostatectomy from 2007-2015 who did not receive neoadjuvant treatment. Of those, 2159 (59%) had complete follow-up for metastasis through 2015 and represented the pool from which the casecohort sample was drawn.

Case-cohort

The case-cohort was originally assembled to include as "cases" men with metastasis or with biochemical recurrence (BCR) with a rapid PSA doubling time (<10 months) who were also considered to be at high risk of metastasis⁴¹. From the cohort of 2159 patients, a subcohort of 244 patients was selected, and 115 cases (73 with BCR and rapid PSA doubling time, and 42 with metastasis). Tissue samples from these men were analyzed for PACC; samples from 307 men were informative for PACC. To focus specifically on risk of metastasis as the outcome of interest, we excluded 65 "men with BCR and rapid PSA doubling time but without metastasis who were included as "cases" in the original case-cohort. This resulting in a subcohort of 209 patients (including 8 metastasis cases), and 30 metastasis cases not in the subcohort, all of whom were informative for PACCs.

Tissue Microarrays (TMAs)

Prostate TMAs were prepared from formalin-fixed paraffin-embedded blocks of the radical prostatectomy specimens. A total of 2807 tissue samples of matched normal/benign and cancer were arrayed in 9 TMA blocks. These TMAs were all constructed as described 41-44 from the index tumor (highest grade) with a 3-4 fold sampling redundancy. On H&E stained tissue sections and TMA sections, identifying PACCs is difficult since they often have indistinct cell membranes therefore making it difficult to distinguish "pseudo" multinucleation from the real ones. Also, unlike many other types of adenocarcinoma and poorly differentiated carcinomas (e.g. high grade urothelial carcinomas. non-small cell lung carcinomas), easily recognizable multinucleated or bizarrely enlarged nuclei are not readily apparent in the vast majority of even very high grade cases. Therefore, we used immunohistochemistry against EpCAM (mouse monoclonal antibody; ABCAM ab7504, Cambridge, UK) on these TMAs to visualize the epithelial cell membranes.. All TMA slides were scanned on a Hamamatsu Nanozoomer and imported into Concentriq (from Proscia). The whole slide scan files were evaluated by two pathologists (LT and AMD). PACCs were defined as the large multi-nucleated or poly-lobated cells that are at least three times the size of a neighboring tumor cell as assessed by visual inspection ³⁹. The presence of PACCs and the number of PACCs on each core were noted.

Statistical Analyses

Descriptive statistics were used to compare cases and subcohort, including Wilcoxon rank sum test for continuous variables and Fisher's exact test or chi-square test for categorical variables. Correlations between PACCs and clinical variables were performed with linear regression or analysis of variance (ANOVA). The primary outcome was metastasis confirmed by imaging, and metastasisfree survival (MFS) was measured from the date of radical prostatectomy. Multivariable Cox proportional hazards regression models, with weights for the case-cohort design and robust variance estimator defined by Barlow (29) were fit to metastasis-free survival (MFS) to evaluate the hazard ratio (HR) and 95% confidence interval (CI) associated with PACCs, adjusted for established prognostic factors or Cancer of the Prostate Risk Assessment Post-surgical (CAPRA-S) score. The CAPRA-S score combines pathologic Gleason score, pathologic stage, surgical margin status and preoperative prostate specific antigen (PSA) in an algorithm with values ranging from 0-12; scores of 6 or higher are considered to indicate high risk of biochemical recurrence (12). Improvement in multivariable model fit for addition of PACCs was assessed with the pseudo-likelihood ratio test for the change in deviance from the full versus the reduced model (30). In addition to the primary outcome of MFS, follow-up for development of mCRPC was available for 33 of the men with metastases. Time from diagnosis of metastasis to mCRPC was analyzed using standard proportional hazards regression, and improvement in model fit was assessed with the likelihood ratio test. All analyses were performed with SAS v. 9.4 (SAS Institute, Cary, NC).

Results

Since the great majority of prostatic adenocarcinomas do not frequently show bizarre nuclear atypia with extremely large nuclei or multinucleation that is readily apparent by H&E staining, we

performed IHC against EpCAM to facilitate the recognition of cellular plasma membranes. This greatly aided in the ability to confidently identify PACCs (Fig. 1 and Supplemental Fig. 1), which in this study were limited to cells with multiple nuclei bounded by a single plasma membrane. Table 1 compares the metastasis cases to men without metastasis. Cases had the expected higher risk profile, differing significantly for all variables except age. Although many patient tumor samples had none, PACCs were significantly more frequent in cases with metastasis, 20 of 38 cases (52.6%), vs. 68 of 201 (33.8%) controls, p=0.029.

The total number of PACCs and the total number of cores with PACCs were significantly correlated with increasing Gleason score (p=0.0004) and increasing CAPRA-S (p=0.004), but no other variables.

In univariate proportional hazards models of MFS, year of surgery, Gleason score (9-10 vs. 7-8), pathology stage, CAPRA-S, total PACCs, and cores positive for PACCs (both evaluated as a continuous variable or dichotomized at >1 vs. 0) were all statistically significant (Table 2). Note that dichotomizing total PACCs and cores positive for PACCs gave the same distribution so the hazard ratios (HRs), 95% confidence intervals (Cls), and p-values are the same.

The multivariable models with PACCs that gave the best fit included CAPRA-S. Adding either total PACCs or cores positive for PACCs (both expressed as a continuous variable) to CAPRA-S both significantly improved model fit compared to CAPRA-S alone, based on the pseudo-likelihood ratio test (Table 3). The best-fitting model included total PACCs, HR=2.00 (95% CI 1.40, 2.87), and CAPRA-S, HR=2.51 (95% CI 1.81, 3.48).

Among 38 patients with metastases, 32 had complete data on PGCCs, CAPRA-S, and time to mCRPC. Table 4 shows univariate analyses for CAPRA-S and total PACCs (expressed as a continuous variable), and the multivariable model of total PACCs and CAPRA-S. Cores positive for PACCs was not statistically significant in a univariate model or adjusted for CAPRA-S (data not shown). Total PACCs was statistically significant in the univariate model, HR=1.23 (95% CI 1.06, 1.43), p=0.007, but was no longer significant when adjusted for CAPRA-S, HR=1.17 (95% CI 0.995, 1.38), p=0.057. The small sample size resulted in a lack of statistical power, which may have influenced the result.

Discussion

The major cause of death related to PCa is the development of therapy resistant metastatic disease. The possible mechanisms of therapy resistance in PCa have been broadly investigated with multiple candidates such as SOX2 activation, MYC and RAS co-activation, and ERG gene rearrangements ^{45–47}. However, the PACC state may represent an inclusive and unifying explanation for therapy resistance mechanisms that is under-recognized. This cell state is induced by the tumor microenvironment or therapeutic stress, can exist for an extended period of time, and can act as a CSC by undergoing depolyploidization and repopulating the tumor cell population when stress is relieved. In order to systematically study this phenomenon, one needs to go back to the fundamental approach to tumor pathogenesis: cell morphology.

PACCs have two defining characteristics: polyploidy and relatively large size. Polyploidy does not necessarily mean "multi-nucleation" and can be pronounced as a single large nucleus; however, multi-nucleated cells are often polyploid. Because of the increased genomic content, polyploid cells are physically larger than the neighboring tumor cells ¹². The presence of PACCs has been shown to be associated with worse prognosis, higher tumor grade, poor differentiation, and advanced disease stage in various tumor types including PCa ^{30,32,34,36,37,40}. There is also evidence in castration-resistant PCa that PACCs drive resistance to taxane-based chemotherapy⁴⁸.

In this study, we investigated the presence of cells in the PACC state and their clinical importance in patients who underwent radical prostatectomy with curative intent to treat their presumed localized PCa. Our findings show that the number of PACCs and the number of cores positive for PACCs are statistically significant prognostic factors for metastasis-free survival, after adjusting for CAPRA-S, in a case-cohort of intermediate or high-risk men who underwent radical prostatectomy. In addition, despite the small number of men with complete data to evaluate time to mCRPC, the total number of PACCs was a statistically significant predictor of mCRPC in univariate analysis, and suggested a prognostic effect even after adjusting for CAPRA-S. To our knowledge, our study is the first to describe the adverse clinical implications of the presence and amount of PACCs in a stratified cohort of PCa patients based on the metastasis status. Assessing the prognostic value of PACCs for mCRPC by employing a larger cohort, prospective analyses of the predictive value of

PACCs for adverse clinical outcome, and, ultimately, whole genome and RNA sequencing of the genetic material of these cells by using microdissection methods are of interest in understanding the biology of PACCs. It should be pointed out, however, that none of the PACCs-associated variables in **Table 2** was as strong as Gleason score, pathological stage or CAPRA-S.

One of the main challenges in this study was to accurately identify PACCs. We found the EpCAM stain helpful in visualizing the larger and atypical tumoral cells and increasing our ability to detect PACCs of various morphologies. It is clear that using a specific biomarker to highlight PACCs would be the ideal approach in studying these cells. However, there are currently no biomarkers for PACCs, either for monitoring in vivo or for isolation, and we believe this should be an area for future research.

Another challenge that might have affected the results of this study is tumor heterogeneity, which has long been known to be present in prostate cancer ⁴⁹, given the fact that we employed TMAs to detect PACCs in our cohort. Although we applied a 3-4 fold sampling redundancy to reduce the margin of error, it is clear that the results of this study might have been affected by r under-representation of PACCs because of the heterogeneous nature of prostate cancer.

We did not determine the incremental improvement in the concordance index associated with adding PACCs to the model containing CAPRA-S because we aren't aware of a validated approach to doing so for a case-cohort study design. However, it has been shown that if a variable is a statistically significant addition to a multivariable model it is mathematically equivalent to demonstrating a significant improvement in model performance, and that the test for significance of adding the variable has greater statistical power than a test of increase in concordance index. Since PACCs was statistically significant when added to a model with CAPRA-S it implies that adding the biomarker significantly improved model performance ^{50,51}.

Because of their important role in disease resistance, we believe it is important to eliminate PACCs in treatment of aggressive PCa patients. However, there are no agents to specifically target these cells to date. Their unique biology and phenotype may create therapeutic opportunities as they may have unexpected vulnerabilities. This is a critical area of research in combination with molecular analysis of their genome. Although there is scarce knowledge about the biology of PACCs, we and others have shown their likely role in mediating disease resistance. We present additional evidence that they are significant prognostic factors for metastasis in patients with PCa who underwent radical prostatectomy with curative intent to treat their presumed localized PCa.

Disclosure/Conflict of Interest Statement:

KJP is a consultant for CUE Biopharma, Inc. and holds equity interest in Keystone Biopharma, Inc. BJT has research grants through Johns Hopkins from MDxHealth, Inc., Myriad Genetics, Inc., Opko Health, Inc., and Exact Sciences, Inc.

AMD is a consultant for Merck, Inc and Cepheid Inc. He has sponsored research support from Janssen and Myriad Genetics Inc.

SRA holds equity interest in Keystone Biopharma, Inc.

Funding Statement:

NCI grants U54CA143803, CA163124, CA093900, and CA143055, and the Prostate Cancer Foundation to KJ Pienta; NCI grant P50CA058236, US Department of Defense CDMRP/PCRP (W81XWH-21-0-373), the Patrick C. Walsh Prostate Cancer Research Fund to BJ Trock; U.S. Department of Defense Prostate Cancer Biospecimen Network Site, Grant/Award Number: W81XWH-18-2-0015; National Cancer Institute, Grant/Award Numbers: MCL U01 CA1936390 P30 CA006973; SPORE in Prostate Cancer, Grant/Award Number: P50CA58236; The Prostate Cancer Foundation to AMD; US Department of Defense CDMRP/PCRP (W81XWH-20-10353), the Patrick C. Walsh Prostate Cancer Research Fund and the Prostate Cancer Foundation to SR Amend

References

- Cree IA, Charlton P. Molecular chess? Hallmarks of anti-cancer drug resistance. BMC Cancer. 2017;17(1):10.
- 2. Nikolaou M, Pavlopoulou A, Georgakilas AG, Kyrodimos E. The challenge of drug resistance in cancer treatment: a current overview. Clin Exp Metastasis. 2018;35(4):309-318.
- 3. Aleksakhina SN, Kashyap A, Imyanitov EN. Mechanisms of acquired tumor drug resistance.

- Biochim Biophys Acta Rev Cancer. 2019;1872(2):188310.
- 4. Burrell RA, Swanton C. Tumour heterogeneity and the evolution of polyclonal drug resistance. Mol Oncol. 2014;8(6):1095-1111.
- 5. Shibue T, Weinberg RA, EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat Rev Clin Oncol. 2017;14(10):611-629.
- 6. Dagogo-Jack I, Shaw AT. Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol. 2018:15(2):81-94.
- 7. Luo M, Brooks M, Wicha MS. Epithelial-mesenchymal plasticity of breast cancer stem cells: implications for metastasis and therapeutic resistance. Curr Pharm Des. 2015;21(10):1301-1310.
- Pienta KJ, Hammarlund EU, Axelrod R, Brown JS, Amend SR. Poly-aneuploid cancer cells 8. promote evolvability, generating lethal cancer. Evol Appl. 2020;13(7):1626-1634.
- 9. Pienta KJ, Hammarlund EU, Austin RH, Axelrod R, Brown JS, Amend SR. Cancer cells employ an evolutionarily conserved polyploidization program to resist therapy. Semin Cancer Biol. Published online December 1, 2020. doi:10.1016/j.semcancer.2020.11.016
- Pienta KJ, Hammarlund EU, Brown JS, Amend SR, Axelrod RM. Cancer recurrence and lethality are enabled by enhanced survival and reversible cell cycle arrest of polyaneuploid cells. Proc Natl Acad Sci U S A. 2021;118(7). doi:10.1073/pnas.2020838118
- 11. Virchow R., Chance F. Cellular pathology, as based upon physiological and pathological histology. Twenty lectures delivered in the Pathological institute of Berlin during the months of February, March and April, 1858. De Witt RM, ed. Published online 1860:xxvi, 27-554 p.
- 12. Amend SR, Torga G, Lin KC, et al. Polyploid giant cancer cells: Unrecognized actuators of tumorigenesis, metastasis, and resistance. Prostate. 2019;79(13):1489-1497.
- 13. Mirzayans R, Andrais B, Murray D. Roles of Polyploid/Multinucleated Giant Cancer Cells in Metastasis and Disease Relapse Following Anticancer Treatment. Cancers . 2018;10(4). doi:10.3390/cancers10040118
- 14. Chen J, Niu N, Zhang J, et al. Polyploid Giant Cancer Cells (PGCCs): The Evil Roots of Cancer. Curr Cancer Drug Targets. 2019;19(5):360-367.
- 15. Illidge TM, Cragg MS, Fringes B, Olive P, Erenpreisa JA. Polyploid giant cells provide a survival mechanism for p53 mutant cells after DNA damage. Cell Biol Int. 2000;24(9):621-633.
- 16. Niu N, Mercado-Uribe I, Liu J. Dedifferentiation into blastomere-like cancer stem cells via formation of polyploid giant cancer cells. Oncogene. 2017;36(34):4887-4900.
- Brooks PJ, Glogauer M, McCulloch CA. An Overview of the Derivation and Function of Multinucleated Giant Cells and Their Role in Pathologic Processes. Am J Pathol. 2019;189(6):1145-1158.
- 18. Moein S, Adibi R, da Silva Meirelles L, Nardi NB, Gheisari Y. Cancer regeneration: Polyploid cells are the key drivers of tumor progression. Biochim Biophys Acta Rev Cancer. 2020;1874(2):188408.
- 19. Weihua Z, Lin Q, Ramoth AJ, Fan D, Fidler IJ. Formation of solid tumors by a single multinucleated cancer cell. Cancer. 2011;117(17):4092-4099.
- 20. Rajaraman R, Guernsey DL, Rajaraman MM, Rajaraman SR. Stem cells, senescence, neosis and self-renewal in cancer. Cancer Cell Int. 2006;6:25.
- 21. Dhimolea E, de Matos Simoes R, Kansara D, et al. An Embryonic Diapause-like Adaptation with Suppressed Myc Activity Enables Tumor Treatment Persistence. Cancer Cell. 2021;39(2):240-256.e11.
- 22. Rehman SK, Haynes J, Collignon E, et al. Colorectal Cancer Cells Enter a Diapause-like DTP State to Survive Chemotherapy. Cell. 2021;184(1):226-242.e21.
- 23. Liu J, Niu N, Li X, Zhang X, Sood AK. The life cycle of polyploid giant cancer cells and dormancy in cancer: Opportunities for novel therapeutic interventions. Semin Cancer Biol. Published online October 17, 2021. doi:10.1016/j.semcancer.2021.10.005
- 24. Saini G, Joshi S, Garlapati C, et al. Polyploid giant cancer cell characterization: New frontiers in predicting response to chemotherapy in breast cancer. Semin Cancer Biol. Published online March 22, 2021. doi:10.1016/j.semcancer.2021.03.017
- 25. Imai Y, Morishita S, Ikeda Y, et al. Immunohistochemical and molecular analysis of giant cell carcinoma of the pancreas: a report of three cases. Pancreas. 1999;18(3):308-315.
- 26. Mosnier JF, Balique JG. Pleomorphic giant cell carcinoma of the esophagus with coexpression of cytokeratin and vimentin and neuroendocrine differentiation. Arch Pathol Lab Med. 2000;124(1):135-138.

- 27. O'Connor RC, Hollowell CMP, Laven BA, Yang XJ, Steinberg GD, Zagaja GP. Recurrent giant cell carcinoma of the bladder. J Urol. 2002;167(4):1784.
- 28. Shen R, Wen P. Clear cell renal cell carcinoma with syncytial giant cells: a case report and review of the literature. Arch Pathol Lab Med. 2004;128(12):1435-1438.
- 29. Schwartz HS, Eskew JD, Butler MG. Clonality studies in giant cell tumor of bone. J Orthop Res. 2002;20(2):387-390.
- 30. Fei F, Zhang D, Yang Z, et al. The number of polyploid giant cancer cells and epithelialmesenchymal transition-related proteins are associated with invasion and metastasis in human breast cancer. J Exp Clin Cancer Res. 2015;34:158.
- 31. Zhang S, Mercado-Uribe I, Xing Z, Sun B, Kuang J, Liu J. Generation of cancer stem-like cells through the formation of polyploid giant cancer cells. *Oncogene*. 2014;33(1):116-128.
- 32. Qu Y, Zhang L, Rong Z, He T, Zhang S. Number of glioma polyploid giant cancer cells (PGCCs) associated with vasculogenic mimicry formation and tumor grade in human glioma. J Exp Clin Cancer Res. 2013;32:75.
- 33. Liu G, Wang Y, Fei F, et al. Clinical characteristics and preliminary morphological observation of 47 cases of primary anorectal malignant melanomas. Melanoma Res. 2018;28(6):592-599.
- 34. Liu HT, Xia T, You YW, et al. Characteristics and clinical significance of polyploid giant cancer cells in laryngeal carcinoma. Laryngoscope Investig Otolaryngol. 2021;6(5):1228-1234.
- 35. Gerashchenko BI, Salmina K, Eglitis J, Huna A, Grjunberga V, Erenpreisa J. Disentangling the aneuploidy and senescence paradoxes: a study of triploid breast cancers non-responsive to neoadjuvant therapy. Histochem Cell Biol. 2016;145(4):497-508.
- 36. Lv H, Shi Y, Zhang L, et al. Polyploid giant cancer cells with budding and the expression of cyclin E, S-phase kinase-associated protein 2, stathmin associated with the grading and metastasis in serous ovarian tumor. BMC Cancer. 2014;14:576.
- 37. Zhang D, Yang X, Yang Z, et al. Daughter Cells and Erythroid Cells Budding from PGCCs and Their Clinicopathological Significances in Colorectal Cancer. J Cancer. 2017;8(3):469-478.
- 38. Lopez-Beltran A, Eble JN, Bostwick DG. Pleomorphic giant cell carcinoma of the prostate. Arch Pathol Lab Med. 2005;129(5):683-685.
- 39. Mannan R, Wang X, Bawa PS, et al. Polypoidal giant cancer cells in metastatic castrationresistant prostate cancer: observations from the Michigan Legacy Tissue Program. Med Oncol. 2020;37(3):16.
- 40. Alharbi AM, De Marzo AM, Hicks JL, Lotan TL, Epstein JI. Prostatic Adenocarcinoma With Focal Pleomorphic Giant Cell Features: A Series of 30 Cases. Am J Surg Pathol. 2018;42(10):1286-1296.
- 41. Vidal I, Zheng Q, Hicks JL, et al. GSTP1 positive prostatic adenocarcinomas are more common in Black than White men in the United States. PLoS One. 2021;16(6):e0241934.
- 42. Chaux A, Peskoe SB, Gonzalez-Roibon N, et al. Loss of PTEN expression is associated with increased risk of recurrence after prostatectomy for clinically localized prostate cancer. Mod Pathol. 2012;25(11):1543-1549.
- 43. Gurel B, Iwata T, Koh CM, et al. Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. Mod Pathol. 2008;21(9):1156-1167.
- 44. Faith DA, Isaacs WB, Morgan JD, et al. Trefoil factor 3 overexpression in prostatic carcinoma: prognostic importance using tissue microarrays. Prostate. 2004;61(3):215-227.
- 45. de Wet L, Williams A, Gillard M, et al. SOX2 mediates metabolic reprogramming of prostate cancer cells. Oncogene. 2022;41(8):1190-1202.
- 46. Arriaga JM, Panja S, Alshalalfa M, et al. A MYC and RAS co-activation signature in localized prostate cancer drives bone metastasis and castration resistance. Nat Cancer. 2020;1(11):1082-1096.
- 47. Udager AM, Shi Y, Tomlins SA, et al. Frequent discordance between ERG gene rearrangement and ERG protein expression in a rapid autopsy cohort of patients with lethal, metastatic, castration-resistant prostate cancer. Prostate. 2014;74(12):1199-1208.
- 48. Mittal K, Donthamsetty S, Kaur R, et al. Multinucleated polyploidy drives resistance to Docetaxel chemotherapy in prostate cancer. Br J Cancer. 2017;116(9):1186-1194.
- 49. Haffner MC, Zwart W, Roudier MP, et al. Genomic and phenotypic heterogeneity in prostate cancer. Nat Rev Urol. 2021;18(2):79-92.
- 50. Pepe, M. S., Kerr, K. F., Longton, G., & Wang, Z. (2013). Testing for improvement in prediction model performance. Statistics in medicine, 32(9), 1467-1482.

51. Vickers, A. J., Cronin, A. M., & Begg, C. B. (2011). One statistical test is sufficient for assessing new predictive markers. BMC medical research methodology, 11(1), 1-7.

Variables	Metastases (n=38)	No Metastases (n=201)	p-value
Age, median (IQR)	59 (56-63)	59 (54-65)	0.747
PSA, median (IQR)	7.0 (5.3-8.7)	5.5 (4.3-8.3)	0.028
Race, n (%) White Black Other	32 (16.8) 6 (20.7) 0 (0)	159 (83.3) 23 (79.3) 16 (100.0)	0.167
Prostatectomy year, median (IQR)	2008 (2007-2009)	2009 (2008-2011)	0.014
Prostatectomy Gleason score, n (%) 6 3+4 4+3 8 9-10	0 (0 1 (1.1) 9 (17.3) 6 (30.0) 22 (68.8)	43 (100.0 88 (98.9) 43 (82.7) 14 (70.0) 10 (31.2)	<0.0001
Pathology stage, n (%) Organ confined Extraprostatic extension Seminal vesicle involvement Lymph node involvement	6 (4.8) 10 (13.3) 10 (45.5) 12 (85.7)	118 (95.2) 65 (86.7) 12 (54.5) 2 (14.3)	<0.0001
Surgical margins, n (%) Negative positive	23 (12.2) 14 (30.4)	165 (87.8) 32 (69.6)	0.002
NCCN Risk, n (%) Intermediate High	17 (9.6) 15 (31.3)	160 (90.4) 33 (68.8)	0.0001
Salvage treatment, n (%) None ADT only Radiation only ADT+Radiation	21 (11.0) 4 (66.7) 8 (32.0) 5 (35.7)	170 (89.0) 2 (33.3) 17 (68.0) 9 (64.3)	<0.0001

CAPRA-S, median (IQR)	7 (4-8)	2 (1-4)	<0.0001
Cores with PACCs, median (IQR)	1 (0-2)	0 (0-1)	0.016
Cores with PACCs, n (%)* 0 ≥1	18 (11.9) 20 (22.7)	133 (88.1) 68 (77.3)	0.029
Total number of PACCs, median (IQR)	1 (0-3)	0 (0-1)	0.011
Total number of PACCs, n (%)* 0 ≥1	18 (11.9) 20 (22.7)	133 (88.2) 68 (77.3)	0.029

Abbreviations: IQR, interquartile range; NCCN, National Comprehensive Cancer Network; ADT, androgen deprivation therapy; PACCs, polyaneuploid cancer cells

Table 2. Univariate proportional hazards models of metastasis-free survival in a case-cohort

of intermediate and high risk men

Variables	HR (95% CI)	p-value
Year of surgery	1.50 1.12, 2.02)	0.007
Age	0.99 (0.93, 1.05)	0.671
PSA (per 1 ng/ml)	1.03 (0.996, 1.07)	0.079
Gleason score 7-8 9-10	1.0 13.48 (5.40, 33.65)	<0.0001
Pathologic stage Organ-confined Extra-prostatic extension Seminal vesicle involvement Lymph node involvement	1.0 3.95 (1.27, 12.32) 17.05 (3.83, 75.83) 61.46 (11.58, 326.33)	<0.0001
CAPRA-S (per 1 unit)	2.32 (1.79, 3.01)	<0.0001
Total PACCs (per 1 PACC)	1.38 (1.09, 1.73)	0.006
Total PACCs (≥1 vs. 0)*	2.70 (1.24, 5.86)	0.012
Cores with PACCs (per 1 core)	1.40 (1.004, 1.94)	0.047
Cores with PACCs (≥1 vs. 0)*	2.70 (1.24, 5.86)	0.012

Abbreviations: HR, hazard ratio; CI, confidence interval

^{*} Binary classification of total PACCs and cores with PACCs gives the same distribution

^{*} Binary classification of total PACCs and cores with PACCs gives the same distribution, so results from proportional hazards model are also the same.

Table 3. Multivariable proportional hazards models of metastasis-free survival in a case-

cohort of intermediate and high risk men **Variables** HR (95% CI) p-value p-value for increase in PLRT* compared to **CAPRA-S** alone Model 1 CAPRA-S (per 1 unit) 2.50 (1.81, < 0.0001 < 0.0001 3.46) Total PACCs (per 1 PACC) 2.00 (1.40, 0.0001 2.85) Model 2 2.23 (1.73, < 0.0001 0.076 CAPRA-S (per 1 unit) 2.88) Total PACCs (≥1 vs. 0)** 1.97 (0.54, 0.306 7.24)Model 3 < 0.0001 0.0003 CAPRA-S (per 1 unit) 2.35 (1.79, 3.09) Cores with PACCs (per 1 2.15 (1.23, 0.007 core) 3.78)Model 4 <0.0001 0.076 CAPRA-S (per 1 unit) 2.23 (1.73, 2.88) Cores with PACCs (≥1 vs. 1.97 (0.54, 0.306

Abbreviations: HR, hazard ratio; CI, confidence interval; PLRT, pseudo-likelihood ratio test * The pseudo-likelihood ratio test is based on the change in deviance when one of the PACC

7.24)

0)**

variables is added to a model of CAPRA-S alone.

^{**} Binary classification of total PACCs and cores with PACCs gives the same distribution, so results from proportional hazards model are also the same.

Table 4. Univariate and multivariable proportional hazards models of time from metastasis to mCRPC in a cohort of intermediate and high risk men with metastasis (n=32)

Variables	HR (95% CI)	p-value	p-value for increase in LRT* compared to CAPRA-S alone		
Univariate					
CAPRA-S (per 1 unit)	1.14 (0.97, 1.33)	0.106	n/a		
Total PACCs (per 1 PACC)	1.22 (1.05, 1.42)	0.011	n/a		
Multivariable					
CAPRA-S (per 1 unit)	1.08 (0.93, 1.27)	0.322	0.075		
Total PACCs (per 1 PACC)	1.17 (0.995, 1.38)	0.057			

Abbreviations: HR, hazard ratio; CI, confidence interval; LRT, likelihood ratio test; n/a, not applicable * The likelihood ratio test is based on the change in deviance when total PACCs is added to a model of CAPRA-S alone.



